Cargando…
LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling
BACKGROUND: The genesis of SMAC mimetic drugs is founded on the observation that many cancers amplify IAP proteins to facilitate their survival, and therefore removal of these pathways would re-sensitize the cells towards apoptosis. It has become increasingly clear that SMAC mimetics also interface...
Autores principales: | Afsahi, Arya, Silvestri, Christopher M., Moore, Allyson E., Graham, Carly F., Bacchiochi, Kaylyn, St-Jean, Martine, Baker, Christopher L., Korneluk, Robert G., Beug, Shawn T., LaCasse, Eric C., Bramson, Jonathan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150108/ https://www.ncbi.nlm.nih.gov/pubmed/37138866 http://dx.doi.org/10.3389/fimmu.2023.1179827 |
Ejemplares similares
-
Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells
por: Beug, Shawn T, et al.
Publicado: (2014) -
Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells
por: Beug, Shawn T., et al.
Publicado: (2019) -
Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression
por: Beug, Shawn T., et al.
Publicado: (2018) -
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
por: Shekhar, Tanmay M., et al.
Publicado: (2019) -
The SMAC mimetic LCL-161 selectively targets JAK2(V617F) mutant cells
por: Craver, Brianna M., et al.
Publicado: (2020)